Forefronts and hotspots evolution of the nanomaterial application in anti-tumor immunotherapy: a scientometric analysis

[1] Sung H(2021)Global cancer statistics 2020: GLOBOCAN estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries CA Cancer J Clin 71 209-249

[2] Ferlay J(2021)Fenton/Fenton-like metal-based nanomaterials combine with oxidase for synergistic tumor therapy J Nanobiotechnol 19 325-33

[3] Siegel RL(2021)Cancer statistics, 2021 CA Cancer J Clin 71 7-900

[4] Laversanne M(2019)Nanoengineered immune niches for reprogramming the immunosuppressive tumor microenvironment and enhancing cancer immunotherapy Adv Mater 31 e1803322-78

[5] Soerjomataram I(2019)Immuno-oncology drug development goes global Nat Rev Drug Discov 18 899-1862

[6] Jemal A(2016)Melanoma in 2015: Immune-checkpoint blockade—durable cancer control Nat Rev Clin Oncol 13 77-167

[7] Bray F(2017)FDA approval of tisagenlecleucel: promise and complexities of a $475 000 cancer drug JAMA 318 1861-14

[8] Cao W(2019)Cancer immunoediting and resistance to T cell-based immunotherapy Nat Rev Clin Oncol 16 151-379

[9] Jin M(2017)Promising cancer drugs may speed tumours in some patients Nature 544 13-443

[10] Yang K(2017)Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol 14 365-99

[1] Sung H(2021)Global cancer statistics 2020: GLOBOCAN estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries CA Cancer J Clin 71 209-249

[2] Ferlay J(2021)Fenton/Fenton-like metal-based nanomaterials combine with oxidase for synergistic tumor therapy J Nanobiotechnol 19 325-33

[3] Siegel RL(2021)Cancer statistics, 2021 CA Cancer J Clin 71 7-900

[4] Laversanne M(2019)Nanoengineered immune niches for reprogramming the immunosuppressive tumor microenvironment and enhancing cancer immunotherapy Adv Mater 31 e1803322-78

[5] Soerjomataram I(2019)Immuno-oncology drug development goes global Nat Rev Drug Discov 18 899-1862

[6] Jemal A(2016)Melanoma in 2015: Immune-checkpoint blockade—durable cancer control Nat Rev Clin Oncol 13 77-167

[7] Bray F(2017)FDA approval of tisagenlecleucel: promise and complexities of a $475 000 cancer drug JAMA 318 1861-14

[8] Cao W(2019)Cancer immunoediting and resistance to T cell-based immunotherapy Nat Rev Clin Oncol 16 151-379

[9] Jin M(2017)Promising cancer drugs may speed tumours in some patients Nature 544 13-443

[10] Yang K(2017)Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol 14 365-99